Operator of a medical device company intended to develop a stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties. The company's platform has developed a novel technology which overcomes the limitations of current approaches while simplifying the procedure and its system consists of numerous differentiating features, including a unique modular independently movable dual-catheter system for provisional side-branch stenting, enabling cardiologists to avoid the positioning and mechanical problems they have in the procedures they use now and reduce risk, improve clinical outcomes, save procedure time, recovery time and reduce cost.